Medivir has new CMO

Medivir AB
Appointee name
Pia Baumann


Medivir AB has appointed Pia Baumann, an oncology specialist, as chief medical officer to help oversee development of fostroxacitabine bralpamide, a pro-drug for the treatment of cancer. She was most recently vice president, medical, at AstraZeneca Plc with global responsibility for Tagrisso, and the company’s lung cancer franchise. Before that, she held executive positions in cancer drug development at Takeda Pharmaceutical Co, Incyte Corporation and ARIAD Pharmaceuticals Inc.

Medivir announced the appointment on 21 February March 2023.

Copyright 2023 Evernow Publishing Ltd